Seoulin Bioscience (Korea) Top Management
038070 Stock | KRW 7,340 230.00 3.23% |
Seoulin Bioscience employs about 91 people. The company is managed by 11 executives with a total tenure of roughly 88 years, averaging almost 8.0 years of service per executive, having 8.27 employees per reported executive. Analysis of Seoulin Bioscience's management performance can provide insight into the company performance.
Eul Hwang CEO Chief Executive Officer, Director |
Seoulin |
Seoulin Bioscience Management Team Effectiveness
The company has return on total asset (ROA) of 0.0554 % which means that it generated a profit of $0.0554 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 10.8133 %, meaning that it generated $10.8133 on every $100 dollars invested by stockholders. Seoulin Bioscience's management efficiency ratios could be used to measure how well Seoulin Bioscience manages its routine affairs as well as how well it operates its assets and liabilities.Seoulin Bioscience Workforce Comparison
Seoulin Bioscience CoLtd is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 855. Seoulin Bioscience retains roughly 91.0 in number of employees claiming about 11% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.22 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.1 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.1. Seoulin Bioscience CoLtd Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Seoulin Bioscience CoLtd Price Series Summation is a cross summation of Seoulin Bioscience price series and its benchmark/peer.
Seoulin Bioscience Notable Stakeholders
A Seoulin Bioscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Seoulin Bioscience often face trade-offs trying to please all of them. Seoulin Bioscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Seoulin Bioscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Eul Hwang | Chief Executive Officer, Director | Profile | |
Wung Jeon | Non-Executive Independent Director | Profile | |
Mi Kang | Assistant Managing Director | Profile | |
Gi Choi | Managing Director | Profile | |
Geol Choi | Managing Director | Profile | |
Jong Ahn | Managing Director | Profile | |
Jae Oh | Internal Auditor | Profile | |
NaeDong Kim | Director Director | Profile | |
KulYong Choi | Director Director | Profile | |
Gil SiYang | Chief Director | Profile | |
IkYoung Kim | Advising Director | Profile |
About Seoulin Bioscience Management Performance
The success or failure of an entity such as Seoulin Bioscience CoLtd often depends on how effective the management is. Seoulin Bioscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Seoulin management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Seoulin management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea. The company was founded in 1984 and is headquartered in Seongnam, South Korea. SeouLin is traded on Korean Securities Dealers Automated Quotations in South Korea.
Please note, the presentation of Seoulin Bioscience's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Seoulin Bioscience's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Seoulin Bioscience's management manipulating its earnings.
Seoulin Bioscience Workforce Analysis
Traditionally, organizations such as Seoulin Bioscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Seoulin Bioscience within its industry.Seoulin Bioscience Manpower Efficiency
Return on Seoulin Bioscience Manpower
Revenue Per Employee | 887M | |
Revenue Per Executive | 7.3B | |
Net Income Per Employee | 173.3M | |
Net Income Per Executive | 1.4B | |
Working Capital Per Employee | 259.8M | |
Working Capital Per Executive | 2.1B |
Complementary Tools for Seoulin Stock analysis
When running Seoulin Bioscience's price analysis, check to measure Seoulin Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Seoulin Bioscience is operating at the current time. Most of Seoulin Bioscience's value examination focuses on studying past and present price action to predict the probability of Seoulin Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Seoulin Bioscience's price. Additionally, you may evaluate how the addition of Seoulin Bioscience to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Transaction History View history of all your transactions and understand their impact on performance | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Bonds Directory Find actively traded corporate debentures issued by US companies |